Six-Year JUPITER-02 Follow-up Results Show LOQTORZI® plus Chemo Nearly Doubles Median OS in NPC December 9, 2025
Crescent Biopharma Announces Partnership with Kelun-Biotech and $185M Private Placement for Next Gen Therapeutics for Solid Tumors December 9, 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant OS improvement for Asian patients with EGFR-mutated NSCLC in the Ph 3 MARIPOSA study December 9, 2025
Global Registrational Ph 3 Study of Olverembatinib in 1L Ph+ ALL Cleared by FDA and EMA December 9, 2025
First US Commercial Sale of KOMZIFTI™ Triggers $135M Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin December 9, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 9, 2025
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for TNBC December 9, 2025
Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines December 9, 2025
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness December 9, 2025
First Patient Dosed in Ph 1/2 Trial of CRN09682 for the Treatment of NETs and Other Somatostatin Receptor 2-Expressing Tumors December 9, 2025
Results from Ph 2 POC study of HLX43 in recurrent/metastatic cervical cancer published December 9, 2025
Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients December 9, 2025
Encouraging Efficacy and Safety Profile from Ongoing Ph 1 Trial for JANX007 in mCRPC Announced December 9, 2025
First-in-Human Data from Ph 1 Trial of GTA182 in MTAP-Deleted Advanced NSCLC presented December 9, 2025
Clinically Meaningful OS Benefit for Gotistobart in Patients with Previously Treated Squamous NSCLC Announced December 9, 2025
